M
Mary Lou Clements
Researcher at Johns Hopkins University
Publications - 90
Citations - 7901
Mary Lou Clements is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Virus & Vaccination. The author has an hindex of 46, co-authored 90 publications receiving 7765 citations. Previous affiliations of Mary Lou Clements include GlaxoSmithKline & University of Hamburg.
Papers
More filters
Journal ArticleDOI
Experimental Campylobacter jejuni Infection in Humans
Robert E. Black,Myron M. Levine,Myron M. Levine,Mary Lou Clements,Mary Lou Clements,Timothy P. Hughes,Timothy P. Hughes,Martin J. Blaser,Martin J. Blaser +8 more
TL;DR: Two strains of Campylobacter jejuni ingested by 111 adult volunteers, in doses ranging from 8 x 10(2) to 2x 10(9) organisms, caused diarrheal illnesses that indicates that the pathogenesis of C.Jejuni infection includes tissue inflammation.
Journal ArticleDOI
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.
TL;DR: A review of available information leads to the conclusion that an oral vaccine consisting of a combination of antigens, intending to stimulate both antibacterial and antitoxic immunity, would be most likely to succeed.
Journal ArticleDOI
The Diarrheal Response of Humans to Some Classic Serotypes of Enteropathogenic Escherichia coli is Dependent on a Plasmid Encoding an Enteroadhesiveness Factor
Myron M. Levine,James P. Nataro,Helge Karch,Mary M. Baldini,James B. Kaper,Robert E. Black,Mary Lou Clements,Alison D. O'Brien +7 more
TL;DR: Diarrhea was caused by 10(8) or 10(10) organisms of an O114:H2 class II EPEC strain in six of 11 volunteers, confirmed that class IIEPEC are pathogenic by a mechanism not involving Hep-2 adhesiveness.
Journal ArticleDOI
Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques.
Myron M. Levine,J B Kaper,D A Herrington,Genevieve Losonsky,J G Morris,Mary Lou Clements,Robert E. Black,Ben D. Tall,R H Hall +8 more
TL;DR: Diarrhea occurred in 7 of 8 controls but in only 1 of 10 vaccines (P less than 0.003, 89% vaccine efficacy), demonstrating the potency of immune mechanisms that do not involve cholera antitoxin.
Journal ArticleDOI
Duration of Infection-Derived Immunity to Cholera
TL;DR: The impressive duration of infection-derived immunity suggests that the most promising approach to development of cholera vaccines may be to mimic natural immunity with orally administered, attenuated strains of V. cholerae.